Focus Partners Wealth’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Focus Partners Wealth’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-36,879	Closed	-$348K	–	2055
2025 Q1	$348K	Sell	36,879 -452	-1%	-$5.27K	﹤0.01%	1504
2024 Q4	$460K	Buy	37,331 +22	+0.1%	+$311	﹤0.01%	1370
2024 Q3	$558K	Sell	37,309 -3,418	-8%	-$50.4K	﹤0.01%	1114
2024 Q2	$550K	Sell	40,727 -1,924	-5%	-$28.5K	﹤0.01%	924
2024 Q1	$709K	Buy	42,651 +11,497	+37%	+$177K	0.01%	660
2023 Q4	$420K	Buy	+31,154	New	+$340K	0.01%	606

Other funds holding CNCR

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Focus Partners Wealth's CNCR Position: Q2 2025 in Review

Focus Partners Wealth sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2025, closing a stake of 36,879 shares — an estimated $348K sold.

Focus Partners Wealth first reported a position in CNCR in Q4 2023 and held it in 6 quarters. The position peaked at $709K in Q1 2024. 1 fund tracked by Wall St. Rank holds CNCR as of Q2 2025.

Focus Partners Wealth reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2025 after selling out during the quarter.
Focus Partners Wealth sold 36,879 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2025, an estimated $348K.
Focus Partners Wealth first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2023 and held it in 6 quarters.
Focus Partners Wealth's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $709K in Q1 2024.
1 fund tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2025.

Based on Focus Partners Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.